Abstract The occurrence of heteroplasmy and mixtures is technically challenging for the analysis of mitochondrial DNA. More than that, observed mutations need to be carefully interpreted in the light of the phylogeny as mitochondrial DNA is a uniparental marker reflecting human evolution. Earlier attempts to explain the role of mtDNA in cancerous tissues led to substantial confusion in medical genetics mainly due to the presentation of low sequence data quality and misinterpretation of mutations representing a particular haplogroup background rather than being cancer-specific. The focus of this study is to characterize the extent and level of mutations in breast cancer samples obtained by tissue microdissection by application of an evaluated full mtDNA genome sequencing protocol. We amplified and sequenced the complete mitochondrial genomes of microdissected breast cancer cells of 15 patients and compared the results to those obtained from paired noncancerous breast tissue derived from the same patients. We observed differences in the heteroplasmic states of substitutions between cancerous and normal cells, one of which was affecting a position that has been previously reported in lung cancer and another one that has been identified in 16 epithelial ovarian tumors, possibly indicating functional relevance. In the coding region, we found full transitions in two cancerous mitochondrial genomes and 12 heteroplasmic substitutions as compared to the non-cancerous breast cells. We identified somatic mutations over the entire mtDNA of human breast cancer cells potentially impairing the mitochondrial OXPHOS system.
dysfunction [1] [2] [3] . The role of mtDNA mutations in cancer has been discussed since the reporting of several somatic mutations in various types of cancer [4] . Whereas the majority of the initial studies focused on the non-coding part of the mtDNA, namely the control region, the analysis of the coding region was targeted in detail more recently [5] . Mitochondrial DNA sequence analysis is technically challenging due to complex phenomena such as heteroplasmy and mixtures of mtDNA types that overlay when characterized by direct sequence analysis, but also due to the fact that observed mutations-with respect to control or reference sequences-need to be carefully interpreted in the light of the phylogeny, particularly in the medical context. Hence, investigations on mtDNA mutations in cancer differed profoundly in data quality and their interpretation as discussed in [6] . Still, the literature displays studies that need to be re-evaluated [7] . A recent study by He et al. [8] which is the first study comparing tumor to normal mtDNA with a second generation sequencing approach uncovers widespread heteroplasmy in normal cells as well as heteroplasmy and homoplasmy in cancer cells. Very surprisingly, the mtDNA of an individual that belongs to mitochondrial haplogroup J1c3a1 obviously lacks signature mutations on positions 15326, 2706, 4216, 3010, and 13934. By all means this is an unusual finding as these positions are yet considered to be stable in the phylogeny [9] and should be re-evaluated in that respect. Despite this fact, there is convincing evidence that a general feature of cancer cells is the accumulation of somatic mutations scattered throughout the entire mitochondrial genome [10] . Theoretically, the high frequency of mtDNA variation in cancer may be explained by neutral random drift in clonally expanding cell populations [11] . However, the selective advantage of mtDNA changes in the development of tumors cannot be excluded either [12] . Recent findings by Beerenwinkel et al. [13] support the theory that tumors contain both neutral mutations (passengers) as well as a smaller fraction of positively selected mutations (drivers) promoting tumor progression.
Assessment of tumor development and progression by sequence analysis gets technically challenging when heteroplasmic mixtures contain a minor contribution of about 10% of the total signal [6, 7, 14] highlighting the paramount role of using appropriate quality of mtDNA raw data to prevent misinterpretation of the data. We have successfully designed a strategy for the amplification and Sanger sequencing of full mitochondrial genomes with reproducible high data quality [15] . Only a systematic investigation of a representative number of tumor cells and corresponding normal cells allows for a meaningful evaluation of the role of mtDNA mutations for the development of cancer and the discussion of functional consequences. However, for the time being, there is insufficient reliable mtDNA data available addressing the comparison between neoplastic versus normal breast cancer cells.
In this study, we performed a full mitochondrial genome analysis for somatic mutations in paired cancerous and non-cancerous tissues from 15 patients with diagnosed breast cancer using our evaluated protocols. The main aim of this study is to characterize the number and proportion in heteroplasmic mixtures of somatic mutations in primary cancerous tissues in comparison to non-cancerous cells of the same individual.
Materials and methods

Clinical samples
Samples derived from patients with diagnosed invasive mamma carcinoma upon mastectomy or tumorectomy under informed and written consent. Criteria for exclusion were tumors which were smaller than 0.5 cm in diameter as well as non-invasive tumors. The study received declaration of no objection by the ethical committee of the Innsbruck Medical University.
Tissue specimens
Frozen and paraffin-embedded tissue samples were obtained directly from breast cancer patients who had undergone tumorectomy or mastectomy after fine needle biopsy diagnosis of breast cancer. The specimens were cooled in ice/water immediately and brought to the pathologist who performed a rapid section and isolated a frozen tissue slice that was embedded in Tissue-Tek OCT Compound (Sakura Finetek Germany GmbH, Staufen, Germany), snap frozen in liquid nitrogen, and stored at -80°C until use. The rest of the tumorectomy was fixed and paraffin-embedded according to standard procedures.
Laser capture tissue microdissection
Frozen sections of the tumor specimens were stained with hematoxylin and eosin for pathological analysis and exact localization of the tumor regions. Parallel, unstained 8 lm frozen sections were used for laser capture microdissection (LCM). Slides were pretreated for 1 min in each of the following cooled solutions: 75% ethanol, DEPC-Water (nuclease-free water), 100% ethanol (twice), xylene (twice), and then air dried. LCM was performed using a PixCell II LCM System (Arcturus Bioscience Inc., Mountain View, CA, USA) with 1,000-3,000 laser impulses for each sample corresponding to about 10,000-30,000 captured cells.
DNA was extracted from single breast cancer and corresponding normal gland cells derived from LCM of the frozen tissue blocks using EZ1 Robotic Workstation and the GenoPrep DNA from Tissue Kit (both Qiagen, Hilden Germany) according to the manufacturer's manual. DNA was resolved in water and quantified via real-time PCR [16] .
MtDNA amplification and sequencing
The entire human mitochondrial genome was amplified and sequenced as previously described [15] . In brief, full mtDNA genomes were amplified as two overlapping fragments of 8.5 kb each in length using aliquots of 5,000 mitochondrial genomes for PCR. Subsequent chain termination sequencing was performed using 96 primers covering the coding region and 10 primers covering the control region [17] . Laser-induced fluorescence capillary electrophoretic separation of purified sequencing products was performed on a 3100 DNA Analyzer (Applied Biosystems, Foster City, CA).
Cloning and sequencing of selected samples 0 -GTGGCAAGAAATGGGCTAC-3 0 and rev 5 0 -GC CAGGTTTCAATTTCTATCG-3 0 flanking position 1632. Ligation of the PCR products into the pCR 4-Blunt-TOPO vector and subsequent transformation into chemically competent One Shot TOP10 E. coli were performed using the Zero Blunt TOPO PCR cloning kit for sequencing (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer's protocol. Transformed cells were incubated at 37°C overnight on LB agar plates containing 50-lg/ml Kanamycin. Small amounts of bacterial colonies were picked using disposable pipette tips, transferred directly to 1.5-ml LB medium supplemented with 50-lg/ml Kanamycin in 96-well deep well plates, and incubated for 18 h at 37°C with constant shaking (200 rpm). Plasmid DNA (pDNA) minipreps from overnight suspension cultures were performed in the 96-well format with the montáge Plasmid Miniprep 96 Kit (Millipore, Billerica, MA, USA) according to the manufacturer's recommendations. 1-ll aliquots of pDNA minipreps were subjected to cycle sequencing (30 cycles comprising 95°C for 15 s, 50°C for 10 s, and 60°C for 4 min after an initial denaturation step of 2 min at 95°C) using the primers M13 for (GTAAAA CGACGGCCAGTGA) and M13 rev (GGAAACAGCT ATGACCATG) and BigDye terminator chemistry (v1.1, Applied Biosystems). Electrophoresis of purified sequencing products was performed using a 3100 DNA Analyzer (Applied Biosystems).
Data analysis and quality assurance
Upon analysis of the raw data the sequences were aligned and the base-calls were reviewed independently by two scientists using the Sequencher software (v.4.8, Gene Codes Corporation, Ann Arbour, MI, USA). Consensus sequences were reported relative to the revised Cambridge Reference Sequence (rCRS) [18, 19] following nomenclature guidelines for mtDNA typing suggested by Carracedo et al. [20] , Tully et al. [21] , and Bandelt and Parson [22] .
Results
Somatic mutations and differences in the control region between breast tumor cells and corresponding normal breast tissue
In the 15 investigated sample pairs of cancerous and corresponding normal breast tissues, we detected six differences in a total of five patients within the mtDNA control region ( Table 1) . Four of the observed heteroplasmic mutations at positions 152, 215, 16304, and 16390 in the control region were also observed by Irwin et al. [23] who investigated the occurrence of point-heteroplasmy in the control region of over 5,000 global population samples. Mutations at positions 152, 16304, and 16390 occur in multiple macro-haplogroup backgrounds (haplogroups L, M, N, and R) [24] , whereas position 215 (8 observations of heteroplasmy in more than 5,000 individuals) is not reported as evolutionary fast site [25, 26] . The remaining two mutations were 16106G/ A and 16391G/ A . 16106A variant was described for haplotypes belonging to European haplogroup T [27] , and 16391A is common in clades I and A2g of haplogroup N [9] . Note that positions 152, 215, and 16391 harbored the heteroplasmic mixture in the normal tissue but were homoplasmic in the tumor. cancerous and corresponding non-cancerous reference tissue, five (35.7%) of which affected ND genes, two (14.3%) were located in the CO genes, four (28.6%) were found in mtRNA genes, and one hit (7.1%) was observed in the cytb gene ( The sensitivity of direct cycle sequencing to reliably display low level mixtures depends on numerous factors including the base composition of the adjacent nucleotide sequence and the uneven ddNTP incorporation rate. To clarify if the apparently fixed somatic mutations found in the tumor cells were actually present at a proportion below the detection limit of sequencing analysis in the normal tissue, clones of PCR products obtained from normal distant tissue samples were sequenced (Table 3) . Therefore, we selected two patients where the corresponding cancerous samples harbored full transitions 12875T (patient 1) and 12131C (patient 11), one patient where the corresponding cancer sample displayed point heteroplasmy (1632C/ T , sample no. 13) and patient 8 whose corresponding cancerous sample harbored a partial transition at the evolutionarily well-conserved position 2998T. None of the analyzed clones displayed any variants that would indicate low level contributions potentially undetected by sequence analysis. The 95% confidence intervals further strengthened the assumption that there was no sequence variation in the corresponding reference tissue samples at positions 12875 (sample no. 1), 12131 (sample no. 11), 1632 (sample no. 13), and 2998 (sample no. 8).
Discussion and conclusions
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The reporting of significantly different numbers of mutations in tumor cells might be also due to the misinterpretation of the resulting electropherograms based on ambiguous data [6] .
Also, the nature of observed mutations in our study differed from other reports. While we found-and confirmed by cloning-2 full transitions and 12 heteroplasmic mutations in the coding region (Table 2 ), the majority of other studies observed largely apparent homoplasmic somatic mutations, for discussion see [5] . Tzen et al. [35] as well as Kassauei et al. [29] observed that several mutations are present in heteroplasmy in healthy counterparts and became homoplasmic in cancer tissues. This is an interesting fact as the level of heteroplasmy is supposed to influence the phenotype in a way that if the pathogenic threshold is surpassed cellular dysfunction caused by defective mitochondria becomes apparent. This also explains the time-related and tissue-specific variability of clinical features displayed in mtDNA-related disorders. Hence, it is remarkable that Park et al. [36] found that a cell line carrying a heteroplasmic ND5 mtDNA mutation showed significantly enhanced tumor growth, while cells with the homoplasmic mutant variant inhibited tumor formation. In contrast, in a study of Petros et al. [37] , the introduction of the homoplasmic variant 8993G in a prostate cancer cell line led to a 7 times larger tumor growth in the resulting cybrid cell line as compared to the wild-type cybrids.
It is further worth mentioning that one cancer sample in our study harbored a mutation at the same position as observed by Aikhionbare et al. [38] in 16 out of 102 epithelial ovarian tumors. In our case, position 1632 (tRNAVal ) was affected by a heteroplasmic transition to C, while Aikhionbare et al. [38] reported transversions to G in all the observed tumor samples. A phylogenetic analysis of different species suggested that site 1632 is conserved (Fig. 2) but might mean that the transversion has a more deleterious effect than the transition. Another interesting finding is the co-occurrence of mutational events at position 2998 (16S rRNA) in one cancer sample of this study and in a lung cancer sample published by Lorenc et al. [39] . While we found a heteroplasmic transition to C at that position, Lorenc et al. reported an insertion. Evolutionary comparisons suggested this position being a highly conserved site and, therefore, an alteration of this position might have functional consequences.
The main yet unexplained question is: when do these mutations actually arise? Do the detected mutations induce cancer development, thus being present at very low levels in pre-cancer states, or does cancer induce mutations? In a study of Wang et al. [10] one of the two detected cancer variants (8601G) also occurred in the paracancerous tissue, and the homoplasmic variant in the tumor arose either through random drift or selection, while the other detected cancer variant (2275C) arose only in the tumor, which was confirmed by subsequent cloning. In our study, tumor specificity of two apparently homoplasmic mutations in the ND4 and ND5 genes at positions 12875 and 12131 was confirmed by cloning and subsequent sequencing of the corresponding mtDNA segments from the normal tissue samples, for which only the wild-type alleles were found. These findings support the model of induction of mutations within the tumor. Contrary, a study of Tzeng et al. [35] showed that mutations were found in 13 out of 53 analyzed ND4 genes of tumor cells but could also be identified in 11 samples of the corresponding normal tissues by DHPLC, indicating that most mtDNA mutations identified in tumors pre-existed already as minor components in heteroplasmic mixtures. These results suggested that mtDNA mutation occurred before tumorigenesis and became apparent in cancer cells.
MtDNA mutations in tumors obviously do not emerge randomly over the entire genome but rather affect phylogenetic informative positions as well as evolutionary fast sites, at least in the control region [40] . This is also evident in our data, as transitions affecting positions 16390 and 16391 are found across the entire phylogeny and positions 152 as well as 16304 are known mutational hotspots [9] . Four of the observed mutations on positions 152, 215, 16304, and 16390 were also determined as frequent hits at heteroplasmic sites in the control region of more than 5,000 global population samples [23] . Only position 215 was not reported as evolutionary fast site [25, 26] and therefore selection against it cannot be excluded, in particular as position 215 is situated close to the origin of heavy-strand replication and a mutation there might influence mtDNA replication [5, 23] . On the contrary, 215T can be found in sublineages of all four major macro-haplogroups M, N, R, and L [9] . 16106A is a rare variant which has been observed in seven of 115 haplotypes of an alpine population [24, 27] . It has been shown in a cell culture system that the rate of ROS-induced lesions was 5-fold higher in the control region as compared to the coding region [41] . In the coding part of the mtDNA, the literature displays the most affected regions to code for Complex I in the electron transport chain [5, 42, 43] which is consistent with our results (35.7% of detected mutations were found in genes coding for Complex I). Functional consequences of these mutations are conceivable as they cause amino acid changes from serine to proline (12131C) and from isoleucine to threonine (12875C). It is possible that a small fraction of mutations act as driver mutations having functional consequences. This assumption goes with the findings of Zhidkov et al. [44] providing evidence for similar selective constraints for the patterns in mtDNA mutations in tumors and human evolution reflecting a response to positive selection pressures in cancer, rather than a random adaptive process.
On the contrary, mutations can become homoplasmic during the process of clonal expansion of tumor cells, representing a model of ''rapid evolution''. This theory is in agreement with the findings of Coller et al. [11] who explained the existence of homoplasmy in tumors solely as a consequence of tumor kinetics without any needs for positive selection, although they do not exclude the possibility of other mechanisms.
In conclusion, we identified somatic mutations over the entire mtDNA of human breast cancer cells potentially impairing the mitochondrial OXPHOS system. Two mutations affected positions that have already been reported by others. Our results suggest that mtDNA mutations may play an important role in the progression of breast cancer, but the mechanism by which mtDNA mutations contribute to cancer development remains unclear. Clearly, there is still more data needed from full mitochondrial genomes of cancer and corresponding non-cancerous tissues to get more insight in the processes involved.
